ARIAD Announces Ponatinib Presentations at Annual American Society of Hematology Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 3, 2012 - ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the presentations on ponatinib, its investigational BCR-ABL inhibitor, that will take place at the 54th Annual Meeting of the American Society of Hematology (ASH) being held in Atlanta, December 8 to 11, 2012. Updated and new results on the PACE trial will be featured in five presentations – two oral and three posters.

PACE Trial: 12-Month Follow Up in Chronic Phase Patients

 

 
Title:   A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial
Oral Session:   632. Chronic Myeloid Leukemia - Therapy I Session
Date & Time:   Sunday, December 9, 2012, 4:30 p.m.
Abstract No.:   163
Presenter:   Jorge E. Cortes, M.D. (The University of Texas MD Anderson Cancer Center)

 

Location:   Georgia World Congress Center, A411-A412
 
PACE Trial: Efficacy and Safety in Advanced Phase Patients

 

 
Title:   Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial
Oral Session:   632. Chronic Myeloid Leukemia - Therapy II Session
Date and Time:   Tuesday, December 11, 2012 at 8:00 a.m.
Abstract No.:   915
Presenter:   Hagop M. Kantarjian, M.D. (The University of Texas MD Anderson Cancer Center)
Location:   Georgia World Congress Center, A411-A412
 
PACE Trial: Results According to Prior Tyrosine Kinase Inhibitor Therapy

 

 
Title:   Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP?CML): Results from the PACE Trial
Poster Session:   632. Chronic Myeloid Leukemia - Therapy: Poster III
Date & Time:   Monday, December 10, 2012, 6:00 – 8:00 p.m.
Abstract No.:   3749
Presenter:   Dong-Wook Kim, M.D., Ph.D. (Mary's Hospital, The Catholic University of Korea)
Location:   Georgia World Congress Center, Hall B1-B2
 
PACE Trial: Molecular Response Data

 

 
Title:   Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial
Poster Session:   632. Chronic Myeloid Leukemia - Therapy: Poster III
Date & Time:   Monday, December 10, 2012, 6:00 – 8:00 p.m.
Abstract No.:   3763
Author:   Andreas Hochhaus, M.D., University Medical Center Jena in Germany
Location:   Georgia World Congress Center, Hall B1-B2
 
PACE Trial: Multivariate Analysis of Parameters

 

 
Title:   Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome?Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial
Poster Session:   632. Chronic Myeloid Leukemia - Therapy: Poster III
Date & Time:   Monday, December 10, 2012, 6:00 – 8:00 p.m.
Abstract No.:   3747
Presenter:   Michael Mauro, M.D. (Oregon Health & Science University)
Location:   Georgia World Congress Center, Hall B1-B2
 
Phase 1 Trial: Long-term Results

 

 
Title:   Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study
Poster Session:   632. Chronic Myeloid Leukemia - Therapy: Poster III
Date & Time:   Monday, December 10, 2012, 6:00 – 8:00 p.m.
Abstract No.:   3743
Presenter:   Michael Deininger, M.D., Ph.D. (University of Utah School of Medicine Huntsman Cancer Institute)
Location:   Georgia World Congress Center, Hall B1-B2
     
About ARIAD

ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD's approach to structure-based drug design has led to several internally discovered, molecularly targeted medicines for drug-resistant or difficult-to-treat cancers, including chronic myeloid leukemia and non-small cell lung cancer. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).

 

Contact: ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams, 617-503-7028
Kendra.adams@ariad.com
or
For Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com
 

 

 

Posted: December 2012

View comments

Hide
(web3)